Adenosine kinase is critical for neointima formation after vascular injury by inducing aberrant DNA hypermethylation.
Adenosine Kinase
/ genetics
Animals
Carotid Arteries
/ enzymology
Carotid Artery Injuries
/ enzymology
Cell Proliferation
DNA Methylation
Disease Models, Animal
Epigenesis, Genetic
Humans
Kruppel-Like Factor 4
/ genetics
Mice, Knockout
Muscle, Smooth, Vascular
/ enzymology
Myocytes, Smooth Muscle
/ enzymology
Neointima
Vascular Remodeling
Arterial neointima
DNA methylation
Vascular smooth muscle cells
Adenosine kinase
Journal
Cardiovascular research
ISSN: 1755-3245
Titre abrégé: Cardiovasc Res
Pays: England
ID NLM: 0077427
Informations de publication
Date de publication:
21 01 2021
21 01 2021
Historique:
received:
11
08
2019
revised:
20
01
2020
accepted:
12
02
2020
pubmed:
18
2
2020
medline:
15
12
2021
entrez:
18
2
2020
Statut:
ppublish
Résumé
Adenosine receptors and extracellular adenosine have been demonstrated to modulate vascular smooth muscle cell (VSMC) proliferation and neointima formation. Adenosine kinase (ADK) is a major enzyme regulating intracellular adenosine levels but is function in VSMC remains unclear. Here, we investigated the role of ADK in vascular injury-induced smooth muscle proliferation and delineated the mechanisms underlying its action. We found that ADK expression was higher in the neointima of injured vessels and in platelet-derived growth factor-treated VSMCs. Genetic and pharmacological inhibition of ADK was enough to attenuate arterial injury-induced neointima formation due to inhibition of VSMC proliferation. Mechanistically, using infinium methylation assays and bisulfite sequencing, we showed that ADK metabolized the intracellular adenosine and potentiated the transmethylation pathway, then induced the aberrant DNA hypermethylation. Pharmacological inhibition of aberrant DNA hypermethylation increased KLF4 expression and suppressed VSMC proliferation as well as the neointima formation. Importantly, in human femoral arteries, we observed increased ADK expression and DNA hypermethylation as well as decreased KLF4 expression in neointimal VSMCs of stenotic vessels suggesting that our findings in mice are relevant for human disease and may hold translational significance. Our study unravels a novel mechanism by which ADK promotes VSMC proliferation via inducing aberrant DNA hypermethylation, thereby down-regulating KLF4 expression and promoting neointima formation. These findings advance the possibility of targeting ADK as an epigenetic modulator to combat vascular injury.
Identifiants
pubmed: 32065618
pii: 5739439
doi: 10.1093/cvr/cvaa040
pmc: PMC7820850
doi:
Substances chimiques
Klf4 protein, mouse
0
Kruppel-Like Factor 4
0
Adenosine Kinase
EC 2.7.1.20
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
561-575Subventions
Organisme : NINDS NIH HHS
ID : R01 NS103740
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL126949
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS065957
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL142097
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL134934
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.
Références
Annu Rev Physiol. 2012;74:13-40
pubmed: 22017177
Cardiovasc Res. 2013 Jul 15;99(2):353-63
pubmed: 23667187
Arterioscler Thromb Vasc Biol. 2018 Dec;38(12):2780-2792
pubmed: 30571174
J Clin Invest. 2018 Jun 1;128(6):2473-2486
pubmed: 29558369
Circ Res. 2008 Jun 20;102(12):1548-57
pubmed: 18483411
PLoS One. 2012;7(1):e30635
pubmed: 22295098
Arch Toxicol. 2013 May;87(5):871-81
pubmed: 23423710
Circ Res. 2009 May 22;104(10):1192-200
pubmed: 19372464
Hypertension. 2017 Jul;70(1):209-218
pubmed: 28507174
J Clin Invest. 2014 Jul;124(7):3187-99
pubmed: 24865430
Arterioscler Thromb Vasc Biol. 2003 Oct 1;23(10):1750-3
pubmed: 12947012
Arterioscler Thromb Vasc Biol. 2017 Jan;37(1):84-97
pubmed: 27879253
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
EMBO Rep. 2011 Jan;12(1):56-62
pubmed: 21109779
J Clin Invest. 1992 Feb;89(2):507-11
pubmed: 1531345
IUBMB Life. 2010 Feb;62(2):132-9
pubmed: 20073036
Endocrinology. 2014 Dec;155(12):4925-38
pubmed: 25251587
Nat Commun. 2017 Oct 16;8(1):943
pubmed: 29038540
Cardiovasc Res. 2000 Apr;46(1):172-9
pubmed: 10727665
Circulation. 2017 Oct 10;136(15):1412-1433
pubmed: 28851732
ACS Chem Biol. 2016 Mar 18;11(3):583-97
pubmed: 26540123
J Clin Invest. 2006 Jan;116(1):36-48
pubmed: 16395403
Circulation. 2013 Oct 29;128(18):2047-57
pubmed: 24077167
Br J Pharmacol. 2012 Apr;165(7):2378-88
pubmed: 22017667
J Am Coll Cardiol. 2004 Aug 18;44(4):733-9
pubmed: 15312851
Hypertension. 1996 Mar;27(3 Pt 2):766-73
pubmed: 8613238
Eur Heart J. 2013 Nov;34(43):3378-88
pubmed: 23008511
EMBO Mol Med. 2017 Sep;9(9):1263-1278
pubmed: 28751580
Am J Physiol Heart Circ Physiol. 2000 Nov;279(5):H2116-23
pubmed: 11045944
Lab Invest. 1983 Aug;49(2):208-15
pubmed: 6876748
J Biol Chem. 2005 Mar 11;280(10):9719-27
pubmed: 15623517
Science. 1979 Aug 31;205(4409):920-2
pubmed: 472713
Curr Pharm Des. 1998 Oct;4(5):403-16
pubmed: 10197052
J Clin Invest. 2013 Aug;123(8):3552-63
pubmed: 23863710
Hypertension. 2015 Dec;66(6):1207-19
pubmed: 26416848
Biochim Biophys Acta. 2015 Apr;1849(4):448-53
pubmed: 24937434
Circ Res. 2015 May 22;116(11):1736-43
pubmed: 25872946
Lab Invest. 1983 Sep;49(3):327-33
pubmed: 6887785
Science. 2011 Sep 2;333(6047):1300-3
pubmed: 21778364
Vasc Cell. 2014 Oct 01;6:21
pubmed: 25309723
Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):792-6
pubmed: 18184815
Proc Natl Acad Sci U S A. 2002 May 14;99(10):6985-90
pubmed: 11997462
Pharmacol Rev. 2013 Apr 16;65(3):906-43
pubmed: 23592612
Curr Top Med Chem. 2005;5(1):43-58
pubmed: 15638777
Hypertension. 2000 Jan;35(1 Pt 2):267-72
pubmed: 10642309